GlobeNewswire by notified

Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T

Share

St. Louis, MO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Curium announced today that the Company has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin its Phase 3 trial with its investigational product lutetium Lu 177 PSMA I&T, a therapeutic radiopharmaceutical that binds to the Prostate-Specific Membrane Antigen (PSMA) protein. Curium is working closely with sites across the U.S. to initiate the ECLIPSE trial (A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer).

If approved, Curium expects to manufacture the product in its Noblesville, Indiana facility, leveraging its centralized production capabilities and logistical expertise. “We are excited about advancing Lu 177 PSMA I&T to the clinical trial stage, particularly in light of our recent announcement for our Cu 64 PSMA I&T imaging agent.  We believe this represents an exciting opportunity for patients nationwide and their healthcare providers,” said Curium CEO, North America, Mike Patterson.

“We are committed to working closely with the FDA to potentially bring this new therapeutic radiopharmaceutical agent to patients and their healthcare professionals,” said Curium Vice President of Medical and Compliance, Ed Porter.  “We look forward to engaging additional clinical trial sites as we finalize our clinical development program.” 

About Curium

Curium is the world’s largest nuclear medicine company. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. 

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for potentially life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. 

To learn more, visit www.curiumpharma.com. For more information about this press release, please contact Janet Ryan, media contact for Curium: janet@ryan-pr.com

CU0056 1021

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS30.11.2021 11:07:00 CET | Press release

RESULT OF RIKSBANK REVERSED AUCTIONS KOMMUNINVEST BONDS Auction date2021-11-30Loan2311Coupon1.00 %ISIN-codeSE0010948240Maturity2023-11-13 Tendered volume, SEK mln750 +/- 1,250 Volume offered, SEK mln2,250 Volume bought, SEK mln750 Number of bids5 Number of accepted bids3 Average yield0.061 %Lowest accepted yield0.054 %Highest yield0.067 %% accepted at lowest yield 100.00 Auction date2021-11-30Loan2505Coupon1.00 %ISIN-codeSE0011414010Maturity2025-05-12 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln1,550 Volume bought, SEK mln630 Number of bids5 Number of accepted bids4 Average yield0.298 %Lowest accepted yield0.265 %Highest yield0.307 %% accepted at lowest yield 16.00 Auction date2021-11-30LoanG23Coupon0.625 %ISIN-codeXS1897258098Maturity2023-06-01 Tendered volume, SEK mln250 +/- 150 Volume offered, SEK mln370 Volume bought, SEK mln120 Number of bids2 Number of accepted bids1 Average yield-0.070 %Lowest accepted yield-0.070 %Highest yield-0.070 %% accepted at lowest yield 1

CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES30.11.2021 09:30:00 CET | Press release

Bid date, 2021-11-30Auction date2021-11-30Settlement date2021-12-01Maturity Date2021-12-08Nominal amount570 billion SEKInterest rate, %0.00Bid times09.30-10.00 (CET/CEST) on the Bid dateConfirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume570 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term1140 billion SEKExpected excess liquidity at full allotment570 billion SEK Stockholm, 2021-11-30

Stratio raises $12M Series A to Scale AI-based Predictive Fleet Maintenance Platform using Real-time Augmented Intelligence30.11.2021 09:02:00 CET | Press release

Investment led by Forestay with participation from existing investor Crane Venture Partners to be used to further accelerate global expansion, increase R&D, boost product development, and double headcount by the end of 2022 LISBON, Portugal and LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Stratio, the world’s leading real-time predictive fleet maintenance platform, today announced a $12M Series A funding round to further accelerate its growth. The investment, led by Forestay Capital, the Deep Tech and SaaS Venture Capital arm of Waypoint Capital, with participation from existing investor Crane Venture Partners, will be used to further accelerate the company’s global expansion, increase its R&D, speed up overall time-to-market, and double its headcount by the end of 2022. Stratio already has its technology deployed in 5 of the top 10 transportation companies in the world and has enabled transportation for 1.3 billion people so far. The company’s Annual Recurring Revenue (ARR) has grown 270

Not intended for U.S. Media – Solvay announces results of its tender offer to purchase bonds for cash30.11.2021 08:32:08 CET | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA OR TO ANY U.S. PERSON OR IN OR INTO ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. Solvay SA continues its deleveraging through the early redemption of bonds due in 2022 Brussels, 30 November 2021 --- Solvay SA (the “Issuer”) today successfully closed the tender offer on its outstanding EUR 750 million 1.625% bonds due 2022, by acquiring €372.5 million of senior debt, marking another step in the strong deleveraging that commenced in 2019. As part of its G.R.O.W. strategy, Solvay has prioritised cash generation and, since January 2019, has generated €2.3 billion operationally, both from improving

Sampo plc’s share buybacks 29/11/202130.11.2021 08:30:00 CET | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 30/11/2021 at 08:30 am Sampo plc’s share buybacks 29/11/2021 On 29/11/2021 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)33,86443.34AQEU34,08143.27CEUX4,67243.25TQEX109,28243.26XHELTOTAL181,89943.28 *rounded to two decimals On 1 October 2021, Sampo announced a share buyback programme of up to a maximum of EUR 750 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 4 October 2021, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 5,631,827 Sampo A shares representing 1.01 per cent of the total number of shares in Sampo plc. Detai

Aino Health AB (publ): Världsledande tillverkare väljer Aino Healths SaaS-lösning HealthManager30.11.2021 08:30:00 CET | Pressemelding

Stockholm 30 November, 2021. Ett världsledande tillverkningsföretag och global marknadsledare inom aggregat-, mineralbearbetnings- och metallraffineringsindustrin har valt att utöka användningen av Aino Healths SaaS-lösning HealthManager. Avtalet innehåller totalt 2 400 licenser, varav 1 300 är nya licenser. "Vi är mycket glada och stolta över att fortsätta och utöka en nyckelaktör inom tillverkningsindustrin som kund. Vi ser fram emot att tillsammans öka personalens välbefinnande och engagemang", säger Jyrki Eklund, VD Aino Health. HealthManager är Ainos egen SaaS-lösning som stödjer chefer med interna hälsorelaterade processer och frånvarohantering. Det erbjuder också rapporterings- och analysverktyg för att följa viktiga mätvärden relaterade till företagets hälsohantering. Målet med lösningen är att digitalisera arbetsförmågasprocesser och öka medarbetarnas engagemang. Om Aino Health (publ) Aino Health är den ledande leverantören av Software as a Service-lösningar inom Corporate Hea